ClinicalTrials.gg
CompletedNCT00263055Updated Sep 15, 2009

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

A Phase 4 interventional study of oxaliplatin in Colonic Neoplasms, sponsored by Sanofi. Completed at 5 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-09-15.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing oxaliplatin in Colonic Neoplasms — 4 open to participants now, 9 under way, 4 of them phase 3. Oxaliplatin · Colonic Neoplasms.

Started
2004
with 9 others
Phase 4
3 of 111
none open now
Registered
54th of 111
by date
Lead sponsor
4 of 111
Sanofi

Among the 111 studies testing oxaliplatin in Colonic Neoplasms, this one is one of 10 that started in 2004, is one of 3 in phase 4, and was the 54th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

4 of the 111 studies testing oxaliplatin in Colonic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing oxaliplatin in Colonic Neoplasms, or all of them as a file.
02

Study summary

Safety \& tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian patients

03

Conditions studied

  • Colonic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven stage Dukes " B2 " (stage II: T3-T4 N0 M0) and " C " (stage III: any T N1-2 M0) colon carcinoma. The inferior pole of the tumor must be above the peritoneal reflection (> 15 cm from the anal margin).
  • Patients must have undergone complete resection of the primary tumor without gross or microscopic evidence of residual disease
  • Patients must be entered in the study in order to start treatment within 7 weeks after surgery
  • Age 18-75 years old
  • Performance Status ≤ 2 ( > or = 60%)
  • No previous chemotherapy, immunotherapy or radiotherapy
  • No biological major abnormalities : > 1.5 x 10\^9/l, ≥ 100 x 10\^9/l,Serum creatinine ≤ 1.25 times the , total , ASAT / ALAT \< 2 times the upper limit of the normal range,carcinoembryonic antigen \< 10 ng/ml.
  • Documentation of a negative pregnancy test must be available for premenopausal women with intact reproductive organs
  • Men and women who are fertile must use a medically acceptable throughout the treatment period and for 3 months following cessation of treatment with oxaliplatin. Subjects must be made aware, before entering this trial of the risk of becoming pregnant or in fathering children
  • Signed obtained prior to study entry

Exclusion criteria

Exclusion criteria

  • Pregnant or lactating women
  • Women of child bearing potential not using a method
  • Previous cancer of the colon or rectum
  • Previous other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease-free interval of at least 10 years
  • Participation in another clinical trial with any drug within 30 days prior to randomization
  • Peripheral neuropathy (NCI CTC [National Cancer Institute Common Toxicity Criteria] > or = Grade I)
  • Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia
  • History of significant neurologic or psychiatric disorders
  • Active infection

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicity

    Time frame: from the inform consent signed up to the end of the study

Secondary outcomes

  1. Occurrence of one or more adverse event in a patient

    Time frame: From the Informed Consent Form (ICF) signature to the end of the study

  2. Overall distribution of intensity of adverse events

    Time frame: from the inform consnet signed up to the end of the study

  3. Occurrence of particular adverse events and their intensities

    Time frame: from the inform consent signed up to the end of the study

  4. Percent of patients completing study treatment

    Time frame: from the inform consent signed up to the end of the study

  5. Percent of patients with grade 1, 2 and 3 neuropathy

    Time frame: at 28 days, 6 months and 12 months after last chemotherapy administration.

  6. Percent of intended dose delivered for 5-FU/LV and Oxaliplatin

    Time frame: from the informed consent signed up to the end of the study

  7. Delays in scheduled dosing

    Time frame: During the study conduct

  8. Dose intensity, as expressed as the amount of 5-FU/LV and Oxaliplatin administered divided by the duration of treatment

    Time frame: during the study conduct

  9. •Survival Analysis •Laboratory assay and vital signs ECOG and KPS

    Time frame: during the study conduct

  10. Long term toxicity

    Time frame: during the study conduct

07

Study locations

5 sites
  • Sanofi-Aventis
    Beijing, China
  • Sanofi-Aventis
    Hong Kong, Hong Kong
  • Sanofi-aventis
    Seoul, Korea, Republic of
  • Sanofi-Aventis
    Taipei, Taiwan
  • Sanofi-Aventis
    Bangkok, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004 and a primary completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2005
First posted
Dec 7, 2005
Start
Aug 2004
Primary completionActual
Jun 2005
Last update
Sep 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00263055
Lead sponsor
Sanofi
First posted
Dec 7, 2005
Start date
Aug 2004
Primary completion
Jun 2005
Last update
Sep 15, 2009

Study contacts

Claude Valterio, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion